Literature DB >> 8785018

Risks and benefits of interferon-alpha in the treatment of hepatitis.

M Pardo1, E Marriott, M C Moliner, J A Quiroga, V Carreño.   

Abstract

The high worldwide prevalence of chronic viral hepatitis, as well as its progressive course, have led to the performance of multiple clinical studies. The natural history of the disease is different depending on the infecting virus; thus, the evolution to liver cirrhosis and/or hepatocellular carcinoma for the hepatitis B, C and delta (D) viruses in chronic hepatitis is 15, 20 and 75%, respectively. Different therapeutic agents have been used in attempts to modify the natural course of these diseases, interferon-alpha (IFN alpha) having proved to be the most effective. In 30 to 50% of patients, treatment with IFN alpha has achieved inhibition of viral replication, as well as normalisation of aminotransferase levels. Moreover, in a majority of patients, histological improvement is observed, principally in piece-meal necrosis and portal inflammation. The dosage currently recommended for treatment of chronic hepatitis B is 30 to 35MU weekly for a minimum of 4 months; when there is a co-existing delta virus infection, the total dosage employed should be greater. For hepatitis C, the minimum effective dosage is 9MU weekly, and a treatment duration of 12 months is recommended. The administration of IFN alpha produces a series of dose-dependent adverse effects, which are reversible on suspension of the medication. The most frequent of these adverse reactions is the 'flu-like' syndrome, which is self-limited and generally well tolerated. Secondary haematological alterations (leucopenia and thrombocytopenia) are the most frequent cause of reduction in dosage or suspension of treatment, although the latter is not normally necessary. The proportion of patients requiring dosage modification or suspension of treatment fluctuates between 5 and 15%. Taking the evolution of chronic hepatitis into account, there can be no doubt that all patients with this disease should be offered treatment. At present, the drug of choice is IFN alpha, as it slows disease progression and it is generally well tolerated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8785018     DOI: 10.2165/00002018-199513050-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  119 in total

1.  Increase in triglycerides during alpha-interferon treatment of chronic viral hepatitis.

Authors:  M Ruiz-Moreno; V Carreño; M J Rúa; T Cotonat; B Serrano; M Santos; E Marriott
Journal:  J Hepatol       Date:  1992-11       Impact factor: 25.083

2.  Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations.

Authors:  R P Perrillo
Journal:  Hepatology       Date:  1990-12       Impact factor: 17.425

3.  Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a.

Authors:  F Negro; M Baldi; A Mondardini; G Leandro; M Chaneac; P Manzini; M L Abate; F Zahm; G Dastoli; M Ballaré
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

4.  Purification and characterization of a human Mx protein.

Authors:  G Weitz; J Bekisz; K Zoon; H Arnheiter
Journal:  J Interferon Res       Date:  1989-12

5.  Psychiatric complications of long-term interferon alfa therapy.

Authors:  P F Renault; J H Hoofnagle; Y Park; K D Mullen; M Peters; D B Jones; V Rustgi; E A Jones
Journal:  Arch Intern Med       Date:  1987-09

6.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

7.  Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities.

Authors:  E Silini; F Bono; A Cividini; A Cerino; S Bruno; S Rossi; G Belloni; B Brugnetti; E Civardi; L Salvaneschi
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

8.  Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy.

Authors:  M Shindo; K Arai; Y Sokawa; T Okuno
Journal:  Ann Intern Med       Date:  1995-04-15       Impact factor: 25.391

9.  Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response.

Authors:  G Mazzella; A Salzetta; S Casanova; M C Morelli; N Villanova; R Miniero; S Sottili; V Novelli; A Cipolla; D Festi
Journal:  Dig Dis Sci       Date:  1994-04       Impact factor: 3.199

10.  Effect of interferon on glucose tolerance and insulin sensitivity.

Authors:  V A Koivisto; R Pelkonen; K Cantell
Journal:  Diabetes       Date:  1989-05       Impact factor: 9.461

View more
  2 in total

1.  Dramatic response to granulocytapheresis in a Crohn's disease case complicated by hepatitis C virus.

Authors:  Koji Sawada; Kunio Ohnishi; Takeshi Kusaka; Yoshika Matoba; Ken Fukunaga
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

2.  Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens.

Authors:  M Schmid; A Kreil; W Jessner; M Homoncik; C Datz; A Gangl; P Ferenci; M Peck-Radosavljevic
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.